Ergomed (ERGO)

 

ERGO Share PerformanceMore

52 week high215.00 06/02/17
52 week low117.00 16/09/16
52 week change 43.00 (25.75%)
4 week volume643,428 28/01/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Ergomed notes partner's successful financing round

Ergomed has noted that its co-development partner Modus Therapeutics has announced a successful financing round, rais...

Modus Therapeutics Raises SEK 32 Million

RNS Number: 2443X Ergomed plc 20 February 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed notes co-development partner Modus Therapeutics successfully raises SEK 32 million (2.9m) London, UK - 20 February 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the phar...

Broker Forecast - Numis issues a broker note on Ergomed Plc

Numis today reaffirms its buy investment rating on Ergomed Plc (LON:ERGO) and set its price target at 277p.

Broker Forecast - Stifel issues a broker note on Ergomed Plc

Stifel today reaffirms its buy investment rating on Ergomed Plc (LON:ERGO) and raised its price target to 315p (from 300...

Positive Phase II top-line results of Lorediplon

RNS Number: 0503W Ergomed plc 06 February 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed announces positive Phase II top-line results of co-development partner Ferrer's Lorediplon for the treatment of insomnia London, UK - 6 Febuary 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of spec...

Broker Forecast - N+1 Singer issues a broker note on Ergomed Plc

N+1 Singer today reaffirms its buy investment rating on Ergomed Plc (LON:ERGO) and set its price target at 293p.

Completion of ZoptrexT Phase 3 Clinical Trial

RNS Number: 6392V Ergomed plc 31 January 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed notes co-development partner Aeterna Zentaris Completes Zoptrex Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer with results expected in April London, UK - 31 January 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a com...

25 momentum stocks for 2017

A screen to find stocks exhibiting the most extreme momentum characteristics has thrown up 25 small-cap names. Lee Wi...

Fundamental DataMore

P/E ratio38.889
EPS5.4
Dividend yield0 %

Equity Research (ERGO)

equity development
Ergomed Plc
25/01/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. The recent period end update for Ergomed confirmed...
equity development
Ergomed Plc
15/12/2016
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed...
equity development
Ergomed Plc
11/10/2016
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed...

Latest discussion posts More

  • See management present

    If you would like to hear Stephen Stamp, Chief Finance Officer, present on behalf of Ergomed he will be appearing at our next investor forum on the evening of Wednesday 25th of ...
    17-Jan-2017
    equity_dev
  • Webinar with management

    We will be hosting a webinar with the management of Ergomed tomorrow (Tuesday 27th September) at 11.15. There will be a presentation of the interim results lasting around ...
    26-Sep-2016
    equity_dev

Users' HoldingsMore

Users who hold Ergomed also hold..
GEMFIELDS25%
FEVERTREE DRK25%
LLOYDS GRP.25%
ACCESSO TECH25%
INSPIRED ENERGY25%

Codes & Symbols

ISINGB00BN7ZCY67
SymbolsERGO, LSE:ERGO, ERGO.L, ERGO:LN, LON:ERGO, XLON:ERGO